Ondine Biomedical (LSE:OBI), appointed Prof. Trevor Jones, CBE FMedSci, to lead a new advisory board on the use of its pioneering photodisinfection-based technology to prevent and treat COVID-19.
Ondine’s non-antibiotic antimicrobial technology, called photodisinfection, rapidly destroys pathogens, including the SARS-CoV-2 virus, without causing resistance.
Ondine’s COVID-19 advisory board consists of leading UK experts in the transmission, prevention, and treatment of COVID-19. Prof. Jones is a long-standing adviser to the UK Government on public health matters and has worked extensively on the COVID-19 pandemic response. He is also currently a visiting Prof. at King’s College, London, and advisor to the Academy of Pharmaceutical Sciences. Prof. Jones also has decades of experience in the pharmaceutical industry, including as head of R&D at the Wellcome Foundation and as director general of the Association of the British Pharmaceutical Industry.
“The research we have announced already this year suggests that our photodisinfection technology is a promising treatment for COVID-19, and we look forward to pushing forward with new research, particularly in the UK, in 2022,” Carolyn Cross, CEO of Ondine, said in a statement.
Photodisinfection therapy, which has been proven in Canadian hospitals and clinics over the past decade, can treat and prevent multidrug resistant infections. Ondine’s development pipeline, which includes products to reduce hospital and other healthcare associated infections, has more recently been directed against the SARS-CoV-2 virus variants driving the COVID-19 pandemic.
Ondine’s photodisinfection therapy, Steriwave, works by using a specific
wavelength of laser light to activate photosensitive compounds placed inside the nose. This combination treatment rapidly destroys the cell membranes and surface proteins of pathogens.
Ondine’s technology is approved in a number of jurisdictions and has been awarded CE Mark, as well as qualified infectious disease product and fast track status by the FDA.